ArcherDX Blog



May
24
2019

2019 International Research Challenge Grant

ArcherDX will award 144 reactions (18 kits) each to 3 recipients


May
15
2019

ArcherDX Announces Close of $60M Financing to Advance Companion Diagnostic and Minimal Residual Disease Monitoring Product Portfolio

ArcherDX announced the closing of an up to $60 million Series B financing round led by Perceptive Advisors. The investor syndicate also includes existing investors PBM Capital, Boulder Ventures, Longwood Fund and Peierls Foundation.


Mar
28
2019

ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients

ArcherDX announces collaboration with University College London to Investigate the Novel Use of Cell-Free Tumor DNA to Detect Disease Recurrence in Lung Cancer Patients


Mar
5
2019

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth


Feb
12
2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.


Jan
30
2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.


Jan
8
2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.


Dec
20
2018

How to decipher noisy regions with per-variant sensitivity detection

Background noise isn't static, so why should your sensitivity threshold be static? Traditional limit of detection measurements are based on static thresholds which average this noise, but Archer scientists have recently developed a method to model the noise at each base position requiring only a small set of samples. This method allows for position-specific sensitivity thresholds, termed 95 MDAF, which increases confidence in variant detection in noisy regions.


Oct
11
2018

Validation of the Archer FusionPlex Sarcoma kit

A paper published in The Journal for Molecular Diagnostics shows a direct comparison between the Archer FusionPlex Sarcoma panel and conventional methods for gene fusion detection, including fluorescence in situ hybridization (FISH) and reverse transcriptase-PCR (RT-PCR)

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2019 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.